PMEF
AUPH icon

Point72 Middle East FZE’s Aurinia Pharmaceuticals AUPH Stock Holding History

Point72 Middle East FZE’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-34,643
Closed -$150K – 1635
2022
Q4 		$150K Buy
+34,643
New +$201K 0.01% 1147

Other funds holding AUPH

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Middle East FZE's AUPH Position: Q1 2023 in Review

Point72 Middle East FZE sold out of Aurinia Pharmaceuticals (AUPH) in Q1 2023, closing a stake of 34,643 shares — an estimated $150K sold.

Point72 Middle East FZE first reported a position in AUPH in Q4 2022 and held it in 1 quarter. The position peaked at $150K in Q4 2022. 186 funds tracked by Wall St. Rank hold AUPH as of Q1 2023.

  • Point72 Middle East FZE reported no remaining Aurinia Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Point72 Middle East FZE sold 34,643 Aurinia Pharmaceuticals shares in Q1 2023, an estimated $150K.
  • Point72 Middle East FZE first reported a position in Aurinia Pharmaceuticals in Q4 2022 and held it in 1 quarter.
  • Point72 Middle East FZE's Aurinia Pharmaceuticals position peaked at $150K in Q4 2022.
  • 186 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q1 2023.

Based on Point72 Middle East FZE's 13F filing for Q1 2023, filed 15 May 2023.